Fig. 4.

GW405833 dose dependently reversed CFA-induced mechanical allodynia in both WT and CB₂KO mice (A). The antiallodynic effect of GW405833 (30 mg/kg i.p.) was unaffected by the CB₂ antagonist SR144528 (10 mg/kg i.p.). Mechanical paw withdrawal thresholds in the contralateral paw were not changed by CFA injection or drug treatments (B). Mixed-sex groups were used: WT (C57BL/6J), n = 8; CB₂KO, n = 8. ^#P < 0.05 vs. baseline; *P < 0.05 vs. vehicle (0 mg/kg i.p.); ^P <0.05 vs. GW405833 (3 mg/kg i.p.) BL, preinjection baseline; SR2, CB₂ antagonist SR144528. Ipsilateral, injected paw; contralateral, uninjected paw.